You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-L1 Checkpoint Inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Durvalumab
  • Rintatolimod
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Jun 23, 2023

Hepatocellular Carcinoma Trial in Beijing, Shanghai, Shenyang (SCG101, PD1/PD-L1 checkpoint inhibitor)

Recruiting
  • Hepatocellular Carcinoma
  • SCG101
  • PD1/PD-L1 checkpoint inhibitor
  • Beijing, China
  • +3 more
May 7, 2022

Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Recruiting
  • Graft Rejection
  • +3 more
  • Immune checkpoint inhibitor
  • Guangzhou, Guangdong, China
    Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
Jun 21, 2023

Solid Tumors, Adult Trial in Kaunas (NECVAX-NEO1)

Recruiting
  • Solid Tumors, Adult
  • NECVAX-NEO1
  • Kaunas, Lithuania
    Elona Juozaityte
May 16, 2022

Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 Trial

Recruiting
  • Advanced Clear Cell Renal Cell Carcinoma
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 17, 2022

Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)

Recruiting
  • Locally Advanced Cervical Cancer
  • Villejuif, Val De Marne, France
    Gustave Roussy
Feb 15, 2022

Solid Tumor, Adult Trial in Orlando, Cincinnati (ADA-011, PD(L)-1 inhibitor)

Recruiting
  • Solid Tumor, Adult
  • Orlando, Florida
  • +1 more
Jan 6, 2023

Extensive-Stage Small Cell Lung Cancer Trial in Beijing (Surufatinib, Anti-PD-1/L1)

Not yet recruiting
  • Extensive-Stage Small Cell Lung Cancer
  • Beijing, China
    Chinese PLA General Hospital
Aug 18, 2022

Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral) Trial in Ljubljana (Immune

Recruiting
  • Metastatic Melanoma
  • +3 more
  • Immune checkpoint inhibitor
  • Ljubljana, Slovenia
    Institute of Oncology Ljubljana
May 17, 2023

Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation

Completed
  • Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
  • Anti-PD-1 or anti-PD-L1
  • Montpellier, France
    UH Montpellier
Dec 22, 2021

Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
    • Alton, Illinois
    • +6 more
    May 18, 2022

    Stage IV NSCLC Trial in Heerlen, Maastricht (No interventions)

    Completed
    • Stage IV Non-small Cell Lung Cancer
    • No interventions
    • Heerlen, Netherlands
    • +1 more
    Sep 15, 2021

    Drug Resistance in Immune Checkpoint Inhibitors of Non-small

    Recruiting
    • Non-Small Cell Lung Cancer
    • Anti-PD-1/PD-L1 monoclonal antibody
    • Shanghai, Shanghai, China
      Xiaomin Niu
    Jul 24, 2021

    Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma Trial in Worldwide (INCB086550)

    Active, not recruiting
    • Non Small Cell Lung Cancer
    • +4 more
    • Burgas, Bulgaria
    • +19 more
    Oct 20, 2022

    Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

    Completed
    • Advanced Solid Tumor
    • Inosine 0.2g orally 3 times/day
    • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
    • Beijing, Beijing, China
      Qin li
    Mar 30, 2023

    Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8 Trial in Los Angeles

    Active, not recruiting
    • Bladder Urothelial Carcinoma
    • +3 more
    • Durvalumab
    • +2 more
    • Los Angeles, California
      UCLA / Jonsson Comprehensive Cancer Center
    Dec 2, 2021

    Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

    Not yet recruiting
    • Lung Cancer
    • Centipeda minima+PD-1/PD-L1 inhibitor
    • PD-1/PD-L1 inhibitor
    • (no location specified)
    Feb 17, 2023

    Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

    Completed
    • Gastrointestinal Tumor
    • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
    • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
    • Hangzhou, China
      Zhejiang Hospital
    Sep 1, 2023

    Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

    Not yet recruiting
    • Metastatic Microsatellite-stable Colorectal Cancer
    • (no location specified)
    Sep 1, 2023

    Efficacy, Safety Trial (PD-L1 inhibitor)

    Not yet recruiting
    • Efficacy
    • Safety
    • PD-L1 inhibitor
    • (no location specified)
    Apr 6, 2022

    Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

    Recruiting
    • Advanced Solid Tumor
    • Refractory Tumor
    • Suzhou, China
      The Second Affiliated Hospital of SchoowUniversity
    Mar 29, 2023

    Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint

    Active, not recruiting
    • Recurrent Nasopharyngeal Carcinoma
    • +2 more
    • PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
    • Guangzhou, Guangdong, China
      Yanqun Xiang
    Sep 5, 2022

    NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Carcinoma Breast
    • Suzhou, China
      Second Affiliated Hospital of Soochow University
    Oct 29, 2022

    NSCLC Associated With Leptomeningeal Metastases Trial (Tislelizumab, pemetrexed)

    Not yet recruiting
    • NSCLC Associated With Leptomeningeal Metastases
    • Tislelizumab, pemetrexed
    • (no location specified)
    Nov 21, 2023

    Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

    Not yet recruiting
    • Advanced Non Small Cell Lung Cancer
    • (no location specified)
    Oct 24, 2023